Company: FVN
Filing Date: 2025-03-10
Form Type: DRS/A
Source: 0001829126-25-001610
Chunk: 213

Company: Future Vision II Acquisition Corp.
Filing Date: 2025-03-10
Form: DRS/A
Chunk 213
---
 Vision’s original purpose). Unlike the Future Vision Insiders, if an initial business combination was not consummated by Future Vision within the required time period, the Public Shareholders would receive a pro-rata portion of the trust account, equivalent to their initial investment plus interest. Like the Future Vision Insiders, however, the Future Vision Rights held by the Public Shareholders would expire worthless if no business combination such as the Business Combination is completed by the deadline. The primary potential detriment to the Public Shareholders of the Business Combination is the dilution of their ownership stake in the combined business of between approximately 41.33% (assuming no redemption of Future Vision Ordinary Shares by Public Shareholders) and approximately 71.57% (assuming redemption of 100% of the Future Vision Ordinary Shares held by the Public Shareholders), from approximately 76.22% of Future Vision prior to the Business Combination to between approximately 34.89% (assuming no redemption of Future Vision Ordinary Shares by Public Shareholders) and approximately 4.65% (assuming redemption of 100% of the Future Vision Ordinary Shares held by the Public Shareholders) of New VIWO.

<div align='center'>124</div>

Anticipated Accounting Treatment

The Business Combination will be treated by Future Vision as a “reverse recapitalization” in accordance with GAAP. For accounting purposes, VIWO is considered to be acquiring Future Vision in this transaction. Therefore, for accounting purposes, the Business Combination will be treated as the equivalent of a capital transaction in which VIWO is issuing share for the net assets of Future Vision. The net assets of Future Vision will be stated at historical cost, with no goodwill or other intangible assets recorded. The post-acquisition financial statements of Future Vision will show the consolidated balances and transactions of Future Vision and VIWO as well as comparative financial information of VIWO (the acquirer for accounting purposes).

Regulatory Approvals

The Business Combination and the other transactions contemplated by the Merger Agreement are not subject to any additional federal or state regulatory requirements or approvals, including the Hart-Scott Rodino Antitrust Improvements Act of 1976. Consummation of the Business Combination (and the issuance of the shares to the VIWO shareholders) will require a declaration of effectiveness of the Proxy Statement/Prospectus, listing approval from the Nasdaq Stock Market Inc., and filing of the Plan of Merger with the Cayman Registry.

VIWO will be required to complete securities filing with the China Securities Regulatory Commission to consummate